Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy
Identifieur interne : 002825 ( Main/Exploration ); précédent : 002824; suivant : 002826Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy
Auteurs : H. Lee [États-Unis] ; M. Mendoza [États-Unis] ; T. Dvorozniak [États-Unis] ; E. Chung [États-Unis] ; H. Van Woert [États-Unis] ; D. Yahr [États-Unis]Source :
- Journal of Neural Transmission - Parkinson's Disease and Dementia Section [ 0936-3076 ] ; 1989-09-01.
Abstract
Summary: Platelet MAO activity was measured in 79 Parkinson patients (56 males and 23 females) before and during L-deprenyl therapy. Baseline platelet MAO activity was higher in females than in males with no age dependent differences. During chronic L-deprenyl therapy, MAO activity was inhibited greater than 98%. Four hours after the oral administration of the first 5 mg dose of L-deprenyl, platelet MAO activity was inhibited by 86%. By 24 hours, greater than 98%, inhibition was achieved and this degree of inhibition was maintained during continuous L-deprenyl administration. Following oral administration of 10 mg L-deprenyl once a day versus 5 mg L-deprenyl twice a day, the time course of platelet MAO inhibition was similar. Five days after the termination of chronic L-deprenyl therapy, platelet MAO activity was still inhibited by 96%. MAO activity returned to normal by 2 weeks after stopping L-deprenyl. Platelet MAO activity is a useful method of monitoring bioavailability, compliance, dose-response relationship and optimal dosage schedules for L-deprenyl in Parkinson patients.
Url:
DOI: 10.1007/BF02248668
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy</title><author><name sortKey="Lee, H" sort="Lee, H" uniqKey="Lee H" first="H." last="Lee">H. Lee</name></author><author><name sortKey="Mendoza, M" sort="Mendoza, M" uniqKey="Mendoza M" first="M." last="Mendoza">M. Mendoza</name></author><author><name sortKey="Dvorozniak, T" sort="Dvorozniak, T" uniqKey="Dvorozniak T" first="T." last="Dvorozniak">T. Dvorozniak</name></author><author><name sortKey="Chung, E" sort="Chung, E" uniqKey="Chung E" first="E." last="Chung">E. Chung</name></author><author><name sortKey="Van Woert, H" sort="Van Woert, H" uniqKey="Van Woert H" first="H." last="Van Woert">H. Van Woert</name></author><author><name sortKey="Yahr, D" sort="Yahr, D" uniqKey="Yahr D" first="D." last="Yahr">D. Yahr</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:32FD516143539DE3DA7DA5A8A3EB6C107401AB66</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1007/BF02248668</idno><idno type="url">https://api.istex.fr/document/32FD516143539DE3DA7DA5A8A3EB6C107401AB66/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001562</idno><idno type="wicri:Area/Main/Curation">001332</idno><idno type="wicri:Area/Main/Exploration">002825</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy</title><author><name sortKey="Lee, H" sort="Lee, H" uniqKey="Lee H" first="H." last="Lee">H. Lee</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1137, 10029, New York City, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Mendoza, M" sort="Mendoza, M" uniqKey="Mendoza M" first="M." last="Mendoza">M. Mendoza</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1137, 10029, New York City, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Dvorozniak, T" sort="Dvorozniak, T" uniqKey="Dvorozniak T" first="T." last="Dvorozniak">T. Dvorozniak</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1137, 10029, New York City, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Chung, E" sort="Chung, E" uniqKey="Chung E" first="E." last="Chung">E. Chung</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1137, 10029, New York City, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Van Woert, H" sort="Van Woert, H" uniqKey="Van Woert H" first="H." last="Van Woert">H. Van Woert</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1137, 10029, New York City, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Yahr, D" sort="Yahr, D" uniqKey="Yahr D" first="D." last="Yahr">D. Yahr</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1137, 10029, New York City, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title><title level="j" type="abbrev">J Neural Transm Gen Sect</title><idno type="ISSN">0936-3076</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1989-09-01">1989-09-01</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="189">189</biblScope><biblScope unit="page" to="194">194</biblScope></imprint><idno type="ISSN">0936-3076</idno></series><idno type="istex">32FD516143539DE3DA7DA5A8A3EB6C107401AB66</idno><idno type="DOI">10.1007/BF02248668</idno><idno type="ArticleID">Art5</idno><idno type="ArticleID">BF02248668</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0936-3076</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Platelet MAO activity was measured in 79 Parkinson patients (56 males and 23 females) before and during L-deprenyl therapy. Baseline platelet MAO activity was higher in females than in males with no age dependent differences. During chronic L-deprenyl therapy, MAO activity was inhibited greater than 98%. Four hours after the oral administration of the first 5 mg dose of L-deprenyl, platelet MAO activity was inhibited by 86%. By 24 hours, greater than 98%, inhibition was achieved and this degree of inhibition was maintained during continuous L-deprenyl administration. Following oral administration of 10 mg L-deprenyl once a day versus 5 mg L-deprenyl twice a day, the time course of platelet MAO inhibition was similar. Five days after the termination of chronic L-deprenyl therapy, platelet MAO activity was still inhibited by 96%. MAO activity returned to normal by 2 weeks after stopping L-deprenyl. Platelet MAO activity is a useful method of monitoring bioavailability, compliance, dose-response relationship and optimal dosage schedules for L-deprenyl in Parkinson patients.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Lee, H" sort="Lee, H" uniqKey="Lee H" first="H." last="Lee">H. Lee</name></region><name sortKey="Chung, E" sort="Chung, E" uniqKey="Chung E" first="E." last="Chung">E. Chung</name><name sortKey="Dvorozniak, T" sort="Dvorozniak, T" uniqKey="Dvorozniak T" first="T." last="Dvorozniak">T. Dvorozniak</name><name sortKey="Mendoza, M" sort="Mendoza, M" uniqKey="Mendoza M" first="M." last="Mendoza">M. Mendoza</name><name sortKey="Van Woert, H" sort="Van Woert, H" uniqKey="Van Woert H" first="H." last="Van Woert">H. Van Woert</name><name sortKey="Yahr, D" sort="Yahr, D" uniqKey="Yahr D" first="D." last="Yahr">D. Yahr</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002825 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002825 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:32FD516143539DE3DA7DA5A8A3EB6C107401AB66
|texte= Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy
}}
| This area was generated with Dilib version V0.6.23. |  |